Author Affiliations: Center E. Grossi Paoletti (Drs Simonelli, Sirtori, Franceschini, and Calabresi) and Department of Pharmacological Sciences (Dr Gianazza), Università degli Studi di Milano, and Centro Universitario Dislipidemie (Drs Mombelli, Bondioli, and Sirtori), Department of Internal Medicine (Dr Ferraro), and Laboratory of Genetics (Dr Penco), Ospedale Niguarda Ca’ Granda, Milano, Italy.
An antibody against the lecithin:cholesterol acyltransferase (LCAT) enzyme, which negates cholesterol esterification in plasma, causing severe high-density lipoprotein deficiency (HD), was identified in a woman with a large-cell non-Hodgkin lymphoma. Successful treatment of the lymphoma resulted in clearance of the antibody and complete correction of the defective cholesterol esterification and HD. To our knowledge, an acquired LCAT deficiency leading to severe HD has not been reported previously in association with a malignant disease, and this patient represents the first such documented case.
Simonelli S, Gianazza E, Mombelli G, et al. Severe High-Density Lipoprotein Deficiency Associated With Autoantibodies Against Lecithin:Cholesterol Acyltransferase in Non-Hodgkin Lymphoma. Arch Intern Med. 2012;172(2):179–181. doi:10.1001/archinternmed.2011.661
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: